
### [MONDO:0020117](http://purl.obolibrary.org/obo/MONDO_0020117)
**Label:** alpha granule disease

**Subclasses:** [MONDO:0007686](http://purl.obolibrary.org/obo/MONDO_0007686) (gray platelet syndrome), 

**Corr. equiv. classes:** [OMIM:139090](http://purl.obolibrary.org/obo/OMIM_139090), [OMIM:187900](http://purl.obolibrary.org/obo/OMIM_187900), [Orphanet:721](http://www.orpha.net/ORDO/Orphanet_721), 

**Class expressions from DL-Learner:**

- [HP:0012147](http://purl.obolibrary.org/obo/HP_0012147) (Reduced quantity of Von Willebrand factor) 66.67%
- [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) and [HP:0100763](http://purl.obolibrary.org/obo/HP_0100763) (Abnormality of the lymphatic system) 66.67%
- [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) and [HP:0025408](http://purl.obolibrary.org/obo/HP_0025408) (Abnormal spleen morphology) 66.67%
- [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) and [HP:0025031](http://purl.obolibrary.org/obo/HP_0025031) (Abnormality of the digestive system) 66.67%
- [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) 66.67%
- [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) and [HP:0012147](http://purl.obolibrary.org/obo/HP_0012147) (Reduced quantity of Von Willebrand factor) 66.67%
- [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) and [HP:0012145](http://purl.obolibrary.org/obo/HP_0012145) (Abnormality of multiple cell lineages in the bone marrow) 66.67%
- [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) and [HP:0011974](http://purl.obolibrary.org/obo/HP_0011974) (Myelofibrosis) 66.67%
- [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) and [HP:0011872](http://purl.obolibrary.org/obo/HP_0011872) (Impaired thrombin-induced platelet aggregation) 66.67%
- [HP:0008320](http://purl.obolibrary.org/obo/HP_0008320) (Impaired collagen-induced platelet aggregation) and [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) 66.67%
- [HP:0005561](http://purl.obolibrary.org/obo/HP_0005561) (Abnormality of bone marrow cell morphology) and [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) 66.67%
- [HP:0003679](http://purl.obolibrary.org/obo/HP_0003679) (Pace of progression) and [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) 66.67%
- [HP:0003676](http://purl.obolibrary.org/obo/HP_0003676) (Progressive) and [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) 66.67%
- [HP:0003271](http://purl.obolibrary.org/obo/HP_0003271) (Visceromegaly) and [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) 66.67%
- [HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system) and [HP:0008330](http://purl.obolibrary.org/obo/HP_0008330) (Reduced von Willebrand factor activity) 66.67%


